These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 27663902)

  • 1. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
    Bilen O; Ballantyne CM
    Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bempedoic acid (Nexletol) for lowering LDL-cholesterol.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):53-55. PubMed ID: 32324179
    [No Abstract]   [Full Text] [Related]  

  • 5. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
    Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR
    Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
    Burke AC; Telford DE; Huff MW
    Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
    Paton DM
    Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
    Brandts J; Ray KK
    Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.
    Zagelbaum NK; Yandrapalli S; Nabors C; Frishman WH
    Cardiol Rev; 2019; 27(1):49-56. PubMed ID: 29939848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETC-1002: a future option for lipid disorders?
    Nikolic D; Mikhailidis DP; Davidson MH; Rizzo M; Banach M
    Atherosclerosis; 2014 Dec; 237(2):705-10. PubMed ID: 25463109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
    Ballantyne CM; Bays HE; Louie MJ; Smart J; Zhang Y; Ray KK
    J Am Heart Assoc; 2022 Aug; 11(15):e024531. PubMed ID: 35916348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Bempedoic Acid in Dyslipidemia Management.
    Kelly MS; Sulaica EM; Beavers CJ
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bempedoic acid: Review of a novel therapy in lipid management.
    Delevry D; Gupta EK
    Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bempedoic acid: a promising novel agent for LDL-C lowering.
    Agarwala A; Goldberg AC
    Future Cardiol; 2020 Sep; 16(5):361-371. PubMed ID: 32463301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
    Pinkosky SL; Newton RS; Day EA; Ford RJ; Lhotak S; Austin RC; Birch CM; Smith BK; Filippov S; Groot PHE; Steinberg GR; Lalwani ND
    Nat Commun; 2016 Nov; 7():13457. PubMed ID: 27892461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid.
    Yarrarapu SNS; Goyal A; Venkata VS; Panchal V; Sivasubramanian BP; Du DT; Jakulla RS; Pamulapati H; Afaq MA; Owens S; Dalia T
    J Cardiol; 2024 Jul; 84(1):22-29. PubMed ID: 38521120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.